

Table S5: Plasma antibody responses after 2, 3, and 2 or 3 doses (≥ 4 -fold and ≥ 2 -fold and ≥ 2 or 4-fold) in cohort B children 10–23 months given 1/8 and 1/4 dose of ETVAX + dmLT or placebo (OEVI24).

Group	C2FA/I			CS3			CS5			CS6			LTB IgA			LTB IgG		
	2	3	2or3	2	3	2or3	2	3	2or3	2	3	2or3	2	3	2 or3	2	3	2or3
V 1/8 dose n=20 ≥ 4 -fold resp.	1	4	5	4	6	8	1	4	5	1	2	3	12	13	15	15	13	
≥ 2 fold resp.	6	7	9	5	3	5	3	0	3	3	3	5	6	2	4	3	5	
V1/4 dose n=19 ≥ 4 -fold resp.	4	8	9	2	4	4	3	6	6	0	0	0	8	10	11	6	8	
≥ 2 -fold resp.	2	1	2	4	2	5	2	1	2	1	2	2	5	3	3	6	5	
Total no of V responders (%)	13	20	25	15	15	22	10	10	16	5	6		31	28	33	31	29	
	25/39 (64%)			22/39 (56%)			16/39(41%)			10/39 (26%)			33/39 (85%)			32/37(86%)		
Placebos n=19 PI ≥ 4 -fold resp.	0	2		1	1		2	3		2	3		4	8		4	8	
PI ≥ 2 -fold resp.	6	6		4	2		0	3		1	2		1	4		1	3	
Total no of P responders (%)	13/20 (65%)			7/20 (35%)			8/20 (42%)			6/20 (30%)			12/20 (60%)			12/19 (63%)		

V vs P all responders

ns

ns

ns

ns

p=0.052

p=0.08